Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoronaVac in children and adolescents (Curumim)
NCT05225285Phase 3Unknown
- Sponsor
- Universidade Federal do Espírito Santo
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of coronavac in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Universidade Federal do Espírito Santo. Primary endpoints: Viral neutralization assay at 3 months, Anti-SARS-CoV-2 anti-IgG-S at 3 months and 6 more. Status: unknown.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05225285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225285.